Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Mucosal Healing and anti TNFs in IBD

Author(s): Gert van Assche, Severine Vermeire and Paul Rutgeerts

Affiliation: Department of Gastroenterology, Leuven University Hospitals, 49 Herestraat, Leuven, Belgium.


Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohns disease this concept has only emerged after biological therapies have been evaluated in clinical trials. Systemic steroids dont induce mucosal healing in Crohns disease, but purine analoges and anti TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti TNF agents infliximab, adalimumab and certolizumab. For infliximab mucosal healing is associated with a reduction in hospitalizations and surgeries. On the contrary, the benefit of treating patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered.

Keywords: Mucosal healing, endoscopy, medical therapy, IBD, Crohn's disease, ulcerative colitis

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [227 - 233]
Pages: 7
DOI: 10.2174/138945010790309902
Price: $58